BioSpace News Archive

Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and technology industries, will release its third quarter 2023 financial results before the market opens on Friday, October 27, and will hold a conference call on the same day at 8:00 a.m. Eastern Time to discuss the results.

Jubilant DraxImage Inc., dba Jubilant Radiopharma, a wholly-owned subsidiary of Jubilant Pharma Limited, has entered into an exclusive partnership with Cardiac Imaging, Inc., of Oakbrook Terrace, Illinois, to provide a daily-leased rubidium solution to healthcare facilities interested in performing cardiac PET.

Faeth Therapeutics, a clinical-stage biotechnology company targeting cancer metabolism, today announced the appointment of Debbie Chirnomas M.D., M.P.H., as Chief Medical Officer.

Geron Corporation (Nasdaq: GERN) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for imetelstat, a first-in-class investigational telomerase inhibitor, for the treatment of transfusion-dependent anemia in patients with lower risk myelodysplastic syndromes (MDS).

Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced its nsPFA technology will be featured in a presentation at the Global EP Summit 2023 in Cleveland, OH from September 29th to 30th, 2023.

Cimeio Therapeutics today announced the publication of research in the Journal of Experimental Medicine showing that epitope edited human hematopoietic stem cells (HSCs) can be protected from targeted immunotherapies.

Lexaria Bioscience Corp. announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor to purchase 1,618,330 shares of common stock in a registered direct offering.

Maravai LifeSciences Holdings, Inc. hosted its 2023 Investor R&D Day featuring presentations by Trey Martin, Chief Executive Officer, and other members of the Maravai leadership team that showcased the company’s strong foundation for growth, key differentiators, innovations, and attractive long-term growth outlook.

Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) (“Calliditas”), today announced the presentations of new biomarker and subgroup analyses from the Phase 3 NefIgArd study with Nefecon (TARPEYO® (budesonide) delayed release capsules/Kinpeygo®) in adults with Primary IgA nephropathy (IgAN).

RaySearch Laboratories AB is pleased to announce that the longterm collaboration/partnership with the innovative center EBG MedAustron GmbH in Wiener Neustadt in Austria will be further expanded through a new research agreement.